论文部分内容阅读
目的:分析观察异基因造血干细胞移植(allo-HSCT)改善合并IKZF1(Ikaros家族锌指蛋白1)突变急性淋巴细胞白血病(ALL)的预后的疗效。方法:回顾性分析2013年12月至2017年12月宁波大学附属人民医院血液科和苏州大学附属第一医院血液科收治的80例IKZF1阳性的急性B淋巴细胞白血病(B-ALL)受者的临床资料，其中接受allo-HSCT的48例(A组)，未接受allo-HSCT的32例(B组)，并选择同期46例IKZF1阴性且接受allo-HSCT的病例作为对照组(C组)。分析影响IKZF1阳性B-ALL预后的相关因素。结果:单因素和多因素分析提示首次完全缓解(CR1)时微小残留病灶(MRD)阳性、未行allo-HSCT是IKZF1阳性B-ALL预后不良的独立危险因素。A组3年总存活率(OS，58.0%±7.7%)、3年无白血病存活率(LFS，52.3%±7.4%)，高于B组(32.4%±10.6%、31.2%±9.9%)，n χ2＝4.259，n P＝0.039和n χ2＝3.926，n P＝0.048，差异有统计学意义；A组3年OS(58.0%±7.7%)、3年LFS(52.3%±7.4%)低于C组(63.2%±8.7%、57.7%±8.1%)，n χ2＝1.306，n P＝0.253，n χ2＝0.648，n P＝0.421，差异无统计学意义。n 结论:allo-HSCT是影响IKZF1阳性B-ALL预后的独立因素、可提高该类患者的3年OS和3年LFS。“,”Objective:To explore the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT)in improving the clinical outcomes of B-cell acute lymphoblastic leukemia(B-ALL)with Ikaros family zinc finger 1(IKZF1)mutation.Methods:Clinical data were reviewed for 80 B-ALL patients with IKZF1 mutation. They were divided into transplantation(A, 48cases)and chemotherapy(B, 32 cases)groups. Meanwhile, 46 concurrent cases with negative IKZF1 were selected as control group(C).Results:Positive minimal residual disease(MRD)at first complete remission(CR1)and non-allo-HSCT were independent factors for poor prognosis by uni and multi-variate analyses. The 3-year rates of overall survival or leukemia-free survival (OS/LFS)were significantly higher in group A than those in group B(58.0±7.7% and 32.4±10.6%; 52.3±7.4% and 31.2±9.9%, n P0.05).n Conclusions:As an independent factor predicating an excellent prognosis of B-ALL, Allo-HSCT significantly improves the OS/LFS of patients and their clinical outcomes.